Panorama® prenatal screening

Panorama® prenatal screening

The Panorama Prenatal screening test, now available in partnership with NewGene Limited, is an innovative non-invasive prenatal test (NIPT) that analyses fetal-placental, cell-­free DNA isolated from maternal plasma. Panorama offers highly accurate, comprehensive panels to screen for fetal aneuploidies and microdeletion syndromes.

Safe and accurate

Non-invasive prenatal testing (NIPT) can prompt a diagnostic journey that gives families time to prepare for the birth of a child with a genetic disorder. ACMG recommends that women of all ages be informed that NIPT is the most sensitive screening test for traditionally screened aneuploidies, including Down's syndrome, a position which is also supported by the International Society for Prenatal Diagnosis. While the prevalence of some conditions, such as Down's syndrome, increases with maternal age, microdeletions occur randomly, meaning women of all ages are at equal risk. Panorama NIPT is highly accurate when compared to maternal serum screening and it poses no risk of miscarriage, unlike diagnostic procedures such as amniocentesis.

What is Panorama®?

Panorama is a non-invasive DNA screening test that can give your patients important information about their pregnancy, as early as nine weeks of gestation. Panorama is a proven and market-leading test, with over 500,000 tests performed on patients from 60 countries.  The methodology employed by the test gives the lowest combined false-negative rate of any NIPT currently on the market and zero errors in fetal sex determination.

Panorama incorporates maternal age and fetal fraction into the calculation of every risk score and includes fetal fraction on every report.  Only samples which meet the test quality metrics are reported upon. The observed redraw rate in clinical experience is 4%.

What Panorama® screens for

Panorama is the only non-invasive prenatal screening test that distinguishes between fetal and maternal cell-free DNA thanks to SNP-based sequencing and Natera's proprietary algorithm. Using advanced bioinformatics techniques, Panorama screens for a broad panel of chromosomal conditions, including:

Chromosome Abnormalities:

  • Trisomy 21 (Down’s syndrome)   >99.9% sensitivity
  • Trisomy 18 (Edwards’ syndrome)   >96.4% sensitivity
  • Trisomy 13 (Patau syndrome)   >99.9% sensitivity
  • Triploidy   >99.9% sensitivity

Sex Chromosome Abnormalities:

  • Monosomy X (Turner’s syndrome)   >92.9% sensitivity
  • Klinefelter syndrome   >99.9% sensitivity
  • Triple X syndrome   >99.9% sensitivity
  • XYY syndrome   >99.9% sensitivity

Microdeletions:

  • 22q11.2 deletion syndrome   >95.7% sensitivity
  • 1p36 deletion syndrome   >93.8% - >99.9% sensitivity
  • Prader Willi syndrome   >93.8% - >99.9% sensitivity
  • Angelman syndrome   >93.8% - >99.9% sensitivity
  • Cri-du-chat syndrome   >93.8% - >99.9% sensitivity

Currently, Panorama cannot be used in the following types of pregnancies:

  • Multiple gestation pregnancies with greater than two fetuses
  • Twin pregnancies that have been conceived using a donor egg or a surrogate
  • Pregnancies with a vanishing twin
  • Pregnant women who are bone marrow or solid organ transplant recipients

The advantages of the Panorama® SNP-based method

Panorama is the only commercially available NIPT that specifically analyses single nucleotide polymorphisms (SNPs) to determine chromosome copy number. Validated at fetal fractions as low as 2.8%, this approach sequences cell-free DNA from maternal plasma to infer the fetal genotype. Panorama targets 13,392 SNPs covering chromosomes 21, 18, 13, X, and Y; additional sets of SNPs are targeted for identification of microdeletions. A patented algorithm is then used to determine the chance of fetal chromosome abnormalities and identify fetal sex (when requested).

The ability to differentiate between maternal and fetal placental DNA also enables Panorama to identify the presence of a vanishing twin and to minimise false positives due to maternal abnormalities. Panorama is also uniquely able to identify triploidy and complete molar pregnancies.

Compared to competitor NIPT assays, Panorama has several advantages, with the lowest False Negative rate (0.6% in published clinical trials), highest sensitivity for 22q11.2 deletion syndrome and zero errors in fetal sex determination.

For further details comparing Panorama with other NIPT assays, please consult the 'Why choose Panorama' section of the Natera website.

Offer Panorama® to your patients

To obtain Panorama sample collection kits, please contact NewGene Limited (UK and Republic of Ireland only).
email:  info@newgene.org.uk or telephone:  0191 242 1923.

Contact us

NewGene Limited
Bioscience Building
International Centre for Life
Newcastle upon Tyne
NE1 4EP, UK

Tel: +44 (0)191 242 1923
Fax: +44 (0)191 241 8799
Email: info@newgene.org.uk

Click here for location map

Mon – Fri 08:30 to 17:00, closed Bank Holidays

An ISO 15189 accredited Medical Laboratory company

Š NewGene Limited | Company Number: 06735445

Technology Partners

Agilent Technologies

Agena Bioscience

Illumina

Sophia Genetics

Qiagen

Promega

Enquiry form